Arcutis Biotherapeutics (ARQT) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Arcutis Biotherapeutics (ARQT) do?
Arcutis Biotherapeutics Inc (ARQT) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells topical cream and foam formulations of roflumilast to treat plaque psoriasis and seborrheic dermatitis. Develops topical non-steroidal treatments to address chronic immune-mediated skin diseases. It is worth $3.44B on the market and sold $509.00M over the last year.
- Market cap
- $3.44B
- P/E ratio
- 126.0×
- Annual sales
- $509.00M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 15, 2026
Brands and businesses behind ARQT
- Zoryve: This topical medication generates revenue by selling prescription cream and foam to treat chronic inflammatory skin conditions.
ARQT’s flags, in plain English
Each flag is a number from Arcutis Biotherapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Wide Gross Margin
Gross margin of 91.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earnings Jumping
Profits up 312.1% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.
Stupid Cash
Can pay this year's bills 2.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Priced for Perfection
Priced at 126 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about ARQT
How big is Arcutis Biotherapeutics?
Arcutis Biotherapeutics’ market cap is $3.44B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $509.00M: what customers paid the company over the last year, before any costs.
What is ARQT’s P/E ratio?
ARQT’s P/E ratio is 126.0×. Investors pay about 126.0 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ARQT?
The business relies on a single active molecule, roflumilast, for all commercial product sales. That is one risk on Arcutis Biotherapeutics’ card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Arcutis Biotherapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ARQT’s filings on SEC.gov. The Margin Monkey is research, not advice.
